

CLAIMS

1. An agent for the treatment of hyperglycemia, said agent consisting of cell walls of yeast of the genus *Saccharomyces cerevisiae*, said yeast cell walls having:
 - a total glucan and mannan content of at least 34.0% by mass on a dry matter basis, preferably of at least 40.0% by mass on a dry matter basis and preferably still of at least 45.0% by mass on a dry matter basis, and
 - a glycogen content of less than 10.0% by mass on a dry matter basis, preferably of less than 8.0% by mass on a dry matter basis, preferably still of less than 5.0% by mass on a dry matter basis, and more preferably still of less than 3.0% by mass on a dry matter basis.
2. The agent according to claim 1, in which the yeast cell walls have a total glucan and mannan content of less than or equal to 70% by mass on a dry matter basis.
3. The agent according to either of claims 1 and 2, in which the yeast cell walls have a total glucan and mannan content of 55% to 70% by mass on a dry matter basis, preferably of 60% to 70% by mass, and preferably still of 60% to 65% by mass on a dry matter basis.
4. The agent according to any one of the preceding claims, in which the yeast cell walls have a glycogen content of less than 1.0% by mass on a dry matter basis, preferably of less than 0.1% by mass on a dry matter basis.
5. The agent according to any one of the preceding claims, in which the yeast cell walls have a dry matter content greater than or equal to 90%, preferably greater than or equal to 94% and preferably still

greater than or equal to 96% by mass.

6. An agent for the prevention of hyperglycemia, said agent consisting of yeast cell walls as defined in any one of the preceding claims.

7. The agent according to any one of the preceding claims, characterized in that the hyperglycemia is a hyperglycemia in the case of type 2 diabetes.

8. An agent for the stabilization of glycemia, the agent consisting of yeast cell walls as defined in any one of claims 1 to 5.

9. The agent according to claim 8, for the stabilization of glycemia in the case of type 2 diabetes.

10. A preparation for the treatment of hyperglycemia, preparation comprising yeast cell walls as defined in any one of claims 1 to 5.

11. A preparation for the prevention of hyperglycemia, preparation comprising yeast cell walls as defined in any one of claims 1 to 5.

12. Preparation according to either of claims 10 and 11, characterized in that the hyperglycemia is a hyperglycemia in the case of type 2 diabetes.

13. A preparation for the stabilization of glycemia, preparation comprising yeast cell walls according to any one of claims 1 to 5.

14. The preparation according to claim 13, for the stabilization of glycemia in the case of type 2 diabetes.

15. The use of yeast cell walls according to any one

of claims 1 to 5, in the preparation of a therapeutic composition for the treatment of hyperglycemia.

5 16. The use of yeast cell walls according to any one of claims 1 to 5, in the preparation of a therapeutic composition for the prevention of hyperglycemia.

10 17. The use according to either of claims 15 and 16, characterized in that the hyperglycemia is a hyperglycemia in the case of type 2 diabetes.

15 18. The use of yeast cell walls according to any one of claims 1 to 5, in the preparation of a therapeutic composition for the stabilization of glycemia.

19. The use according to claim 18, for the preparation of a therapeutic composition for the stabilization of glycemia in the case of type 2 diabetes.